Sandoz Launches Denosumab Biosimilars in Europe

Sandoz Group AG has announced the launch of its denosumab biosimilars, Wyost® and Jubbonti®, in Europe. These biosimilars provide affordable treatment options for cancer-related bone diseases and osteoporosis. Approved by the European Commission, Wyost® and Jubbonti® cover all indications of their reference medicines, Xgeva® and Prolia®.

This launch marks a significant step in Sandoz's growth strategy, following launches in the US earlier this year. Christophe Delenta, President Europe of Sandoz, highlighted the importance of expanding access to these medicines for millions affected by bone-related health issues.

Wyost® is indicated for cancer-related bone diseases, while Jubbonti® treats osteoporosis in at-risk populations. With 32 million Europeans over 50 affected by osteoporosis, the demand for effective treatments is critical. The European rollout of these drugs will continue through 2026, fortifying Sandoz's position in the global biosimilar market.